Dulaglutide
Also called Trulicity.
Dulaglutide has FDA-approved products for specific uses. This page cites 1 source, and the strongest evidence comes from human trials.
- Status
- FDA-approved product exists
- Form
- Pen injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 1
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
In REWIND, dulaglutide reduced the composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke compared with placebo in adults with type 2 diabetes and cardiovascular disease or risk factors.
Limits: The trial enrolled 9,901 adults aged at least 50 and followed them for a median 5.4 years. All-cause mortality did not differ significantly. Gastrointestinal events were more frequent with dulaglutide. The result does not establish cardiovascular benefit in people without diabetes.
Regulatory status
United States
As of November 6, 2026, Trulicity is FDA-approved for type 2 diabetes glucose control from age 10 and cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease or multiple risk factors. It has no FDA weight-management indication.